【摘要】 [目的]探讨缬沙坦联合金水宝治疗慢性肾炎蛋白尿的临床疗效。[方法]将2007年1月至2010年2月本院收治的90例慢性肾炎蛋白尿患者按就诊顺序随机分成治疗组和对照组各45例。对照组在基础综合治疗后加用卡托普利片,治疗组加用缬沙坦和金水宝片。两组均连续用药12周后进行疗效评价。[结果]治疗组与对照组相比,治疗后肌酐及尿蛋白定量明显下降,临床症状体征好转,差异均具有统计学意义(P<0.01)。治疗组总缓解率为88.89%,与对照组相比差异有统计学意义(P<0.05)。[结论]缬沙坦联合金水宝治疗慢性肾炎蛋白尿具有疗效显著、副反应小、安全可靠等优点,值得临床推广使用。更多还原

【Abstract】 [Objective] Clinical efficacy of valsartan,jinshuibao treatment of chronic glomerulonephritis.[Methods] 90 patients with chronic glomerul-onephritis in the order of 1:1 according to treatment were randomly divided into treatment group and control group of 45 patients,two groups of patients in gender,age,disease duration,blood urea nitrogen,creatinine,urine protein had no statistically significant difference(P >0.05).All patients were given low-salt,high-calorie,low phosphorus,low-fat,high protein diet,controlling blood pressure,correcting water,electrolyte and acid-base balance,infection control,anticoagulation therapy,and other comprehensive measures to control group with Captopril Tablets 12.5～25 mg,bid,po.Treatment group received valsartan 80 mg,qd,morning,Burton clothing,Jinshuibao 3,tid,po.Both groups after 12 weeks of continuous treatment had efficacy evaluation.[Results]The treatment group compared with the control group after treatment,creatinine and urinary protein significantly decreased,the clinical symptoms and signs improved,the differences were statistically significant(P<0.01).Treatment group,overall response rate was 88.9%(40/45) and control group 71.1%(32/45),the difference was statistically significant(P<0.05).[Conclusion] Jinshuibao valsartan combined treatment of chronic glome-rulonephritis has a significant effect,little side effects,safe and reliable,worthy of clinical use.更多还原